StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a research report issued on Thursday. The brokerage set a “buy” rating on the stock.
Trinity Biotech Trading Down 1.0 %
NASDAQ TRIB opened at $2.06 on Thursday. The firm has a market capitalization of $15.70 million, a price-to-earnings ratio of -0.74 and a beta of 1.16. The firm’s 50 day simple moving average is $1.95 and its 200 day simple moving average is $2.16. Trinity Biotech has a 1 year low of $1.49 and a 1 year high of $5.50.
Trinity Biotech (NASDAQ:TRIB – Get Free Report) last posted its quarterly earnings results on Thursday, May 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter. On average, equities research analysts forecast that Trinity Biotech will post -2.17 earnings per share for the current year.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
See Also
- Five stocks we like better than Trinity Biotech
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
